Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Procuritas in connection with the sale of Ouriginal Group
Mandate

Vinge has advised Procuritas in connection with the sale of Ouriginal Group

January 07, 2022 EU, Competition and Regulatory IT, Telecommunications and Outsourcing M&A Intellectual Property

Vinge has advised Procuritas, the private equity investor focused on investing in and growing Nordic mid-market companies, in connection with the sale of Ouriginal Group to Turnitin LLC, a global leader in academic integrity and education software.

Ouriginal, a company formed from the union of Urkund and PlagScan, has over three decades of experience in combining text-matching with writing-style analysis to promote academic integrity and prevent plagiarism in schools and universities.

Vinge’s team consisted of Jonas Johansson, Karl Klackenberg and Ellinor Wargenbrant (M&A), Mathilda Persson (IT), Tobias Kempas (IP), Sebastian Örndahl and Victoria Fredén (Competition) and Viktoria Owetz Leyva (VDR).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025